Article references (52 references )


  1. American Diabetic Association. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S86-S104. PubMed | Google Scholar

  2. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769-818. Epub 2011 Jun 28. PubMed | Google Scholar

  3. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular disease statistics 2008 edition. European Heart Network. 2008. Brussels. Google Scholar

  4. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. Epub 2017 May 17. PubMed | Google Scholar

  5. World Health Organization. Global Heart Initiative: The Global cardiovascular disease (CVD). 15 September 2016. Accessed 20 August 18.

  6. Dawber TR. The Framingham Study: The epidemiology of atherosclerotic disease. 1980. Cambridge, MA. Harvard University Press.

  7. Mendis S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Prog Cardiovasc Dis. 2010;53(1):10-14. PubMed | Google Scholar

  8. Keys A. Seven countries: A multivariate analysis of death and coronary heart disease. 1980. Cambridge, MA and London. Harvard University Press.

  9. International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussel, Belgium: International Diabetic Federation. 2017.

  10. World Health Organization. Global Health Observatory data: Cholesterol. Accessed 14 Feb 2015.

  11. Levitan EB, Song Y, Ford ES, Lui S. Is non-diabetic hyperglycaemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004; 164(19):2147-2155. PubMed | Google Scholar

  12. Eberly LE, Cohen JD, Prineas R, Yang L; Intervention Trial Research group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: The multiple risk factor intervention trial experience. Diabetes Care. 2003;26(3):848-854. PubMed | Google Scholar

  13. Kannel WB, McGee DL. Diabetes and cardiovascular disease: A Framingham study. JAMA. 1979;241(19):2035-2038. PubMed | Google Scholar

  14. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760-765. Epub 2003 May 28. PubMed | Google Scholar

  15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-44. PubMed | Google Scholar

  16. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicenter randomised placebo-controlled trial. Lancet. 2004;364 (9435):685-96. PubMed | Google Scholar

  17. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. Epub 2005 Sep 27. PubMed | Google Scholar

  18. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12;371(9607):117-25. PubMed | Google Scholar

  19. Grundy SM. Small LDL, Atherogenic dyslipidemia, and metabolic syndrome. Circulation. 1997;95:1-4. PubMed | Google Scholar

  20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. PubMed | Google Scholar

  21. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker forcoronary heart disease risk. Circulation. 1990;82(2):495-506. PubMed | Google Scholar

  22. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Pract. 2017;23(Suppl 2):1-87. PubMed | Google Scholar

  23. Dobiášová M, Frohlich J, Šedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566-571. Epub 2011 Jan 11. PubMed | Google Scholar

  24. Dobiášová M. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. Vnitr Lek. 2006 Jan;52(1):64-71. PubMed | Google Scholar

  25. World Health Organization. A global brief on hypertension. April 2013. Accessed 12 November 2016.

  26. American Diabetes Association. Standards of Medical Care in Diabetes-2016. Diabetes Care 2016 Jan;39(Supplement 1):S1-S2.

  27. World Health Organization. Physical status: the use and interpretation of anthropometry. 1995. Accessed 12 November 2016.

  28. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011. Accessed 13 December 2016.

  29. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908. Epub 2006 Mar 29. PubMed | Google Scholar

  30. Turner RC, Millns H, Neil HA, Strattron IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823-828. PubMed | Google Scholar

  31. Eberly LE, Stamler J, Neaton JD. Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003 May 12;163(9):1077-83. PubMed | Google Scholar

  32. Nordestgaard BG, Benn M, Schnohr P, Tybgaerd-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308. PubMed | Google Scholar

  33. Manisha Mandal, Rina Kumari, Arati Mukherjee. Prevalence of dyslipidemia in patients with type 2 diabetes mellitus: a hospital based study in Kishanganj, India. Int J Res Med Sci. 2015;3(12):3691-3697. Google Scholar

  34. Bekele S, Yohannes T, Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People's Region. Diabetes Met Syndr Obes. 2017 Jun 22;10:265-271. eCollection 2017. PubMed | Google Scholar

  35. Razaq A, Mohammad T, Razaq A. Prevalence of dyslipidemia in newly diagnosed type 2 diabetes patients at diagnosed at KGNTH Bannu. Gomal J Med Sci. 2017;15(4):178-82. Google Scholar

  36. Chamba NG, Shao ER, Sonda T, Lyaruu IA. Lipid Profile of Type 2 Diabetic Patients at a Tertiary Hospital in Tanzania: Cross Sectional Study. J Endocrinol Diab. 2017;4(1)1-6. Google Scholar

  37. Sang VK, Kaduka L, Kamano J, Makworo D. Prevalence of dyslipidemia and the associated factors among Type 2 diabetes patients in Turbo Sub-County, Kenya. J Endocrinol Diab. 2017;4(5):1-9. Google Scholar

  38. Pokharel DR, Khadka D, Sigdel M, Yadav NK, Achary S, Kafle R et al. Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes. BMC Res Notes. 2017 Apr 4;10(1):146. PubMed | Google Scholar

  39. Jan SS, Rehman A, Ahmad R, Khan TM, Ahmad A, Abrar A. Evaluation of pattern of dyslipidemia in Type 2 diabetics in Swat. Gomal J of Med Sci. 2011;9(2):243-46. Google Scholar

  40. Omotoye FE, Fadupin GT. Evaluation of Lipid Profile of Type 2 Diabetic Patients Attending an Urban Tertiary Health Facility in Nigeria. Indian J Nutri. 2017;4(2):159.

  41. Okafor CI, Fasanmade OA, Oke DA. Pattern of dyslipidemia among Nigerians with type 2 DM. Niger J of Clinical Pract. 2008;11(1):25-31. PubMed | Google Scholar

  42. Jisieike-Onuigbo NN, Unuigbe EI, Oguejiofor CO. Dyslipidemias in type 2 diabetes mellitus patients in Nnewi South-East Nigeria. Ann Afr Med. 2011;10(4):285-289. PubMed | Google Scholar

  43. World Health Organization. Cardiovascular disease risk factors: new areas for research, report of a WHO scientific group. 1994 Geneva. Accessed 12 August 2018.

  44. Oguejiofor OC, Onwukwe CH, Odenigbo CU. Dyslipidemia in Nigeria: Prevalence and pattern. Ann Afr Med. 2012;11(4):197-202. PubMed | Google Scholar

  45. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men - Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95(1):69-75. PubMed | Google Scholar

  46. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363-1379. PubMed | Google Scholar

  47. Soran H, France MW, Kwok S, Dissanayake S, Charlton-Menys V, Younis NN et al. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Ann Clin Biochem. 2011 Nov;48(Pt 6):566-71. Epub 2011 Oct 17. PubMed | Google Scholar

  48. Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia. 2003 Jun;46(6):733-49. Epub 2003 May 28. PubMed | Google Scholar

  49. Sugden M, Holness M. Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology. 2011;6(4):401-411. Google Scholar

  50. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1114-20. PubMed | Google Scholar

  51. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992 Sep 15;70(7):733-7. PubMed | Google Scholar

  52. Goel S, Garg PK, Malhotra V, Madan J, Mitra SK, Grover S. Dyslipidemia in Type II Diabetes Mellitus - An assessment of the main lipoprotein abnormalities. Bangladesh Journal of Medical Science. 2016; 15(1):99-102. Google Scholar